No Data
No Data
Yahong Medicine (688176.SH) released its semi-annual performance, with a net loss of 0.184 billion yuan.
Yahong Pharmaceutical (688176.SH) disclosed its 2024 interim report. During the reporting period, the company achieved revenue of 8,049...
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Yahong Medicine (688176.SH): plans to launch a restricted stock incentive plan for 8.3201 million shares.
Gelonghui announced on August 28th that YAHong Pharmaceuticals (688176.SH) has released a restricted stock incentive plan for 2024. The plan plans to grant 8.3201 million restricted stocks to the incentive recipients, accounting for approximately 1.46% of the total shares of the company's capital, which was 570 million shares at the time of the announcement of the incentive plan draft. The grant is a one-time grant with no reserved portions.
Yuhong Pharmaceutical (688176.SH): The revenue in Q2 of 2024 increased by 130.98% month-on-month, and the core products are steadily progressing to market.
On August 28, YAHONG Medicine (688176.SH) released its 2024 interim report. In the first half of 2024, the company achieved revenue of 80.4934 million yuan, with 56.1739 million yuan achieved in the second quarter, a 130.98% increase compared to the previous quarter. In addition, the company is actively promoting the market launch of two core products. The new drug application for APL-1702 has been accepted, and the company is actively advancing the market approval process. Currently, the progress is smooth, and it is expected to become the world's first non-surgical treatment for high-grade squamous intraepithelial lesions of the cervix. APL-1706 has also successfully passed the national drug approval process.
YaHong Medical (688176.SH): has repurchased 1.3608% of the shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company had cumulatively repurchased 7,756,291 shares, accounting for 1.3608% of the total share capital, with a maximum repurchase price of RMB 6.73 per share, and a minimum price of RMB 5.02 per share. The total amount paid was RMB 44.79 million (excluding stamp duty, transaction commission and other trading expenses).
No Data